(Reuters) – Sun Pharmaceutical Industries Ltd, India’s largest drugmaker by sales, said on Wednesday its $3.2 billion acquisition of smaller rival Ranbaxy Laboratories Ltd will not restrict it from making further large acquisitions.
The company will look to invest more than $300 million in research and development and is not considering any job cuts post the close of the deal, Managing Director Dilip Shanghvi told reporters in Mumbai.
Shanghvi, who founded Sun Pharma and is one of the country’s richest men, added that the company’s “most important focus” would be to win confidence of regulators.
Sun Pharma’s third-quarter profit was hit by costs incurred to address observations raised by the U.S. Food and Drug Administration after an inspection of the company’s manufacturing plant in western India.
“Every investment I have made outside of Sun is financial, I have no interest in running those businesses,” said Shanghvi, who invested $290 million for a 23 percent stake in wind turbine maker Suzlon Energy Ltd last month.
The company’s shares were up 1 percent in afternoon trading on Wednesday, while the benchmark index was down 0.16 percent. (Reporting by Zeba Siddiqui in Mumbai; Writing by Aman Shah; Editing by Anand Basu)